{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:09:34Z","timestamp":1778843374659,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1-0189"],"award-info":[{"award-number":["P1-0189"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.msard.2023.104615","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:26:29Z","timestamp":1678854389000},"page":"104615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-1793","authenticated-orcid":false,"given":"Maj","family":"Jo\u017eef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Brecl Jakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uro\u0161","family":"Rot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-6450","authenticated-orcid":false,"given":"Mitja","family":"Kos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104615_bib0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CEOR.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"Clin. Outcomes Res."},{"issue":"7","key":"10.1016\/j.msard.2023.104615_bib0002","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in hypertension","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.msard.2023.104615_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174426","article-title":"Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data","volume":"12","author":"Dima","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.msard.2023.104615_bib0004","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1183\/09031936.00172114","article-title":"Asthma inhaler adherence determinants in adults: systematic review of observational data","volume":"45","author":"Dima","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.msard.2023.104615_bib0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2023.104615_bib0006","first-page":"1165","article-title":"Multiple sclerosis: the role of MR imaging","volume":"27","author":"Ge","year":"2006","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2023.104615_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104615_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2023.104615_bib0009","article-title":"Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up","volume":"3","author":"Hersh","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.104615_bib0010","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann. Pharmacother."},{"issue":"12","key":"10.1016\/j.msard.2023.104615_bib0011","first-page":"1394","article-title":"Adherence to disease-modifying therapies for multiple sclerosis","volume":"22","author":"Higuera","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"8","key":"10.1016\/j.msard.2023.104615_bib0012","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2023.104615_bib0013","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/archneur.1997.00550170015009","article-title":"Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis","volume":"54","author":"Mohr","year":"1997","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2023.104615_bib0021","unstructured":"Multiple Sclerosis International Federation, 2020. Atlas of MS, 3rd Edition (September 2020). Retrieved from: https:\/\/www.atlasofms.org. (accessed February 7th, 2023)."},{"key":"10.1016\/j.msard.2023.104615_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/PPA.S118107","article-title":"An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug","volume":"11","author":"Munsell","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.msard.2023.104615_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12883-020-01830-0","article-title":"Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"20","author":"Nicholas","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2023.104615_bib0016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2133.1998.02400.x","article-title":"The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network","volume":"139","author":"Ockenfels","year":"1998","journal-title":"Br. J. Dermatol."},{"issue":"58-59","key":"10.1016\/j.msard.2023.104615_bib0017","first-page":"28","article-title":"Disease-modifying therapy for multiple sclerosis in Slovenia: analysis of 20 years of treatment","volume":"552","author":"Rot","year":"2022","journal-title":"Rad hrvat. Akad. Znan. Umjet. Med. Znan."},{"key":"10.1016\/j.msard.2023.104615_bib0018","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.msard.2018.11.004","article-title":"Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study","volume":"27","author":"Setayeshgar","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.104615_bib0019","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1177\/1352458509106214","article-title":"Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease","volume":"15","author":"Siva","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104615_bib0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2023.104615_bib0022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1472-6963-12-155","article-title":"Comparison of pharmacy-based measures of medication adherence","volume":"12","author":"Vollmer","year":"2012","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.msard.2023.104615_bib0023","series-title":"Atlas multiple sclerosis resources in the world 2008","year":"2008"},{"issue":"9","key":"10.1016\/j.msard.2023.104615_bib0024","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3111\/13696998.2015.1044276","article-title":"Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis","volume":"18","author":"Yermakov","year":"2015","journal-title":"J. Med. Econ."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:28:35Z","timestamp":1778840915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"alternative-id":["S2211034823001190"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104615","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104615"}}